The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways

[1]  F. Beca,et al.  p-mTOR expression is associated with better prognosis in luminal breast carcinoma , 2014, Journal of Clinical Pathology.

[2]  P. Tighe,et al.  A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS) , 2014, European journal of immunology.

[3]  I. Ellis,et al.  Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study , 2014, Breast Cancer Research and Treatment.

[4]  I. Ellis,et al.  SUMOylation proteins in breast cancer , 2014, Breast Cancer Research and Treatment.

[5]  F. André,et al.  Clinical development of mTOR inhibitors in breast cancer , 2014, Breast Cancer Research.

[6]  L. Murphy,et al.  The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo , 2014, Breast Cancer Research.

[7]  D. Spaeth,et al.  Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study. , 2013 .

[8]  G. Hortobagyi,et al.  Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yong Chen,et al.  MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB , 2012, Autophagy.

[10]  M. Rosner,et al.  p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6 , 2011, Amino Acids.

[11]  J. Renoir,et al.  Cracking the estrogen receptor's posttranslational code in breast tumors. , 2011, Endocrine reviews.

[12]  R. O'Regan,et al.  mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy , 2011, Expert opinion on therapeutic targets.

[13]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[14]  I. Ellis,et al.  Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer , 2012, Breast Cancer Research.

[15]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[16]  I. Ellis,et al.  FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer , 2011, Breast Cancer Research and Treatment.

[17]  D. Sabatini,et al.  mTORC1 controls fasting-induced ketogenesis and its modulation by ageing , 2010, Nature.

[18]  Heiko A. Mannsperger,et al.  RPPanalyzer: Analysis of reverse-phase protein array data , 2010, Bioinform..

[19]  E. Mylona,et al.  Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas , 2010, Histopathology.

[20]  J. Downward,et al.  Rictor is a novel target of p70 S6 kinase-1 , 2010, Oncogene.

[21]  J. P. Kennedy,et al.  Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells , 2009, Clinical Cancer Research.

[22]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[23]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[24]  E. Karapanagiotou,et al.  The role of mTOR in the management of solid tumors: an overview. , 2009, Cancer treatment reviews.

[25]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[26]  Yibing Yan,et al.  Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays , 2008, Molecular Cancer Therapeutics.

[27]  I. Ellis,et al.  Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. , 2008, European journal of cancer.

[28]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[29]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[30]  Goberdhan P Dimri,et al.  Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. , 2007, Cancer research.

[31]  Gangduo Wang,et al.  Requirements of phosphatidylinositol-3 kinase and mammalian target of rapamycin for estrogen-induced proliferation in uterine leiomyoma- and myometrium-derived cell lines. , 2007, American journal of obstetrics and gynecology.

[32]  D. Sabatini,et al.  Stress and mTORture signaling , 2006, Oncogene.

[33]  Tony Hunter,et al.  Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis , 2006, Molecular and Cellular Biology.

[34]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[35]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[36]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[37]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[38]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[39]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[40]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[41]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[42]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.